MAISNAR, Vladimír, J. RADOCHA, Tomáš BÜCHLER, V. BLÁHA, J. MALÝ and Roman HÁJEK. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology. England: Blackwell, 2007, vol. 79, No 4, p. 305-309. ISSN 0902-4441.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment
Name in Czech Monoterapie nízkodávkovaným thalidomidem pro relabovaný a refrakterní mnohočetný myelom: s časnější léčboul epší léčebná odpověď
Authors MAISNAR, Vladimír (203 Czech Republic), J. RADOCHA (203 Czech Republic), Tomáš BÜCHLER (203 Czech Republic), V. BLÁHA (203 Czech Republic), J. MALÝ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor).
Edition European Journal of Haematology, England, Blackwell, 2007, 0902-4441.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.163
RIV identification code RIV/00216224:14110/07:00035883
Organization unit Faculty of Medicine
UT WoS 000249428100006
Keywords (in Czech) mnohočetný myelom;thalidomid;monoterapie
Keywords in English thalidomide; monotherapy; multiple myeloma; treatment; relapse
Tags monotherapy, multiple myeloma, relapse, Thalidomide, treatment
Tags International impact, Reviewed
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 22/6/2009 16:50.
Abstract
Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM). The optimal dosing regimen of thalidomide is not known. Patients and Methods: We retrospectively analysed the overall response rate and response duration of 53 patients with relapsed MM who received thalidomide in a median dose of 100 mg daily. The aim of the study was to compare the response rates of thalidomide given as the second-line treatment to those of thalidomide given as the third-line therapy.
Abstract (in Czech)
Thalidomid je imunomodulační látka používaná při léčbě refrakterního mnohočetného myelomu. V publikaci je popsána léčba 53 pacientů s MM. Cílem studie bylo porovnat léčebné odpovědi pacientů, kteří dostali thalidomid ve druhé linii léčby a třetí linii léčby.
PrintDisplayed: 1/5/2024 09:14